Advanced Oncotherapy PLC (LON:AVO) told investors on Thursday that it has reached another “key milestone” in the development of its LIGHT proton therapy system.
The company has integrated the proton source and radio frequency quadruple (RFQ) following a successful testing programme at ADAM – a research centre in Geneva funded by AVO.
“This work has demonstrated there is a predicted acceleration of the proton beam through this very sophisticated structure, the RFQ, and that the measurements matched those expected from computer simulations,” AVO said in a very technical note to the markets.
“The completion of this key milestone is a significant indicator of the continued successful technical development of the Company's LIGHT proton system.”
The newly-designed RFQ has a notably higher frequency and, hence, shorter wavelength and smaller dimensions than current comparable linear accelerators, AVO said.
This allows for a more targeted and accurate penetration of the cancer cells and should lead to less damage to the surrounding tissue.
Shares closed at 57p on Wednesday.